Business Description
Enlivex Ltd
ISIN : IL0011319527
Total Employee Number:
34Description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.98 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.4 | |||||
3-Year EPS without NRI Growth Rate | 45.7 | |||||
3-Year FCF Growth Rate | 50.1 | |||||
3-Year Book Growth Rate | 38.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 55.89 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.52 | |||||
9-Day RSI | 24.82 | |||||
14-Day RSI | 20.43 | |||||
3-1 Month Momentum % | -59.06 | |||||
6-1 Month Momentum % | -75.65 | |||||
12-1 Month Momentum % | -74.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 193.24 | |||||
Quick Ratio | 193.24 | |||||
Cash Ratio | 0.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -134.4 | |||||
Shareholder Yield % | -37.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | 306.48 | |||||
ROA % | 255.04 | |||||
ROIC % | -3.22 | |||||
3-Year ROIIC % | 0.62 | |||||
ROC (Joel Greenblatt) % | -4.33 | |||||
ROCE % | -3.13 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.02 | |||||
Price-to-Owner-Earnings | 0.02 | |||||
PB Ratio | 0.01 | |||||
Price-to-Tangible-Book | 0.01 | |||||
EV-to-EBIT | -1.43 | |||||
EV-to-EBITDA | -1.46 | |||||
EV-to-FCF | -2.04 | |||||
Price-to-Projected-FCF | 0.02 | |||||
| Price-to-Net-Current-Asset-Value | 0.02 | |||||
Earnings Yield (Greenblatt) % | -69.93 | |||||
FCF Yield % | -39.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENLV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enlivex Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 73.748 | ||
| Beta | 2.625 | ||
| 3-Year Sharpe Ratio | -0.53 | ||
| 3-Year Sortino Ratio | -0.67 | ||
| Volatility % | 99.74 | ||
| 14-Day RSI | 20.43 | ||
| 14-Day ATR ($) | 0.33363 | ||
| 20-Day SMA ($) | 1.79825 | ||
| 12-1 Month Momentum % | -74.07 | ||
| 52-Week Range ($) | 1.39 - 27.149999 | ||
| Shares Outstanding (Mil) | 17.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enlivex Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enlivex Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2025 | 2026-11-13 | In 78 days | ||
| General meeting for 2025 | 2026-11-10 19:00 | In 77 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 1 day | ||
| RedChip Investor Webinar | 2026-07-30 10:00 | 2.25 (-1.75%) | ||
| 0.0666667:1 Stock Split | 2026-07-09 | 7.21 (+1.59%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-03-25 09:00 | 16.50 (+0.92%) | ||
| Annual report for 2025 | 2026-03-25 | 16.50 (+0.92%) | ||
| Fourth quarter earnings results for 2026 | 2026-03-25 | 16.50 (+0.92%) | ||
| Fintech & DATS | 2026-02-04 09:30 | 16.35 (+4.81%) | ||
| Third quarter earnings results for 2024 | 2025-11-14 | 14.85 (-2.93%) |
Show
Entries
Enlivex Ltd Frequently Asked Questions
What is Enlivex Ltd(ENLV)'s stock price today?
The current price of ENLV is $1.52. The 52 week high of ENLV is $27.15 and 52 week low is $1.39.
When is next earnings date of Enlivex Ltd(ENLV)?
The next earnings date of Enlivex Ltd(ENLV) is 2026-08-28 Est..
Does Enlivex Ltd(ENLV) pay dividends? If so, how much?
Enlivex Ltd(ENLV) does not pay dividend.
Press Release
Articles on Enlivex Ltd
ENLV Stockholders Plan Sale of 10 Million Shares Amidst Challenging Valuation Landscape
Aug 06, 2026
H.C. Wainwright Lifts Enlivex Therapeutics (ENLV) Price Target to $80 After Reverse Split
Aug 03, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers